GASTRIC AND GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Clinical trials for GASTRIC AND GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTRIC AND GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTRIC AND GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise in shrinking stomach tumors before surgery
Disease control OngoingThis study tests whether adding the drugs camrelizumab and apatinib to standard chemotherapy (SOX) before surgery can help shrink tumors in people with locally advanced stomach or gastroesophageal junction cancer. About 80 participants will receive the treatment before surgery. T…
Matched conditions: GASTRIC AND GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New triple therapy shows promise in stomach cancer fight
Disease control OngoingThis study tests whether adding the immunotherapy drug camrelizumab to standard chemotherapy and the targeted drug apatinib improves outcomes for people with stomach or gastroesophageal junction cancer that can be surgically removed. About 580 adults will receive the treatment be…
Matched conditions: GASTRIC AND GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC